EA201891571A1 - Геномное профилирование отдельных циркулирующих опухолевых клеток (ctc) при метастазирующем заболевании для характеризации гетерогенности заболевания - Google Patents

Геномное профилирование отдельных циркулирующих опухолевых клеток (ctc) при метастазирующем заболевании для характеризации гетерогенности заболевания

Info

Publication number
EA201891571A1
EA201891571A1 EA201891571A EA201891571A EA201891571A1 EA 201891571 A1 EA201891571 A1 EA 201891571A1 EA 201891571 A EA201891571 A EA 201891571A EA 201891571 A EA201891571 A EA 201891571A EA 201891571 A1 EA201891571 A1 EA 201891571A1
Authority
EA
Eurasian Patent Office
Prior art keywords
disease
ctc
heterogeneity
tumor cells
circulating tumor
Prior art date
Application number
EA201891571A
Other languages
English (en)
Russian (ru)
Inventor
Райан Диттамор
Дена Марринуччи
Original Assignee
Эпик Сайенсиз, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Эпик Сайенсиз, Инк. filed Critical Эпик Сайенсиз, Инк.
Publication of EA201891571A1 publication Critical patent/EA201891571A1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57555—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the prostate
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N15/00—Investigating characteristics of particles; Investigating permeability, pore-volume or surface-area of porous materials
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N15/00—Investigating characteristics of particles; Investigating permeability, pore-volume or surface-area of porous materials
    • G01N15/10—Investigating individual particles
    • G01N15/14—Optical investigation techniques, e.g. flow cytometry
    • G01N15/1429—Signal processing
    • G01N15/1433—Signal processing using image recognition
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5091—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing the pathological state of an organism
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/52—Use of compounds or compositions for colorimetric, spectrophotometric or fluorometric investigation, e.g. use of reagent paper and including single- and multilayer analytical elements
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • G01N33/57585—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites involving compounds identifiable in body fluids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2537/00—Reactions characterised by the reaction format or use of a specific feature
    • C12Q2537/10—Reactions characterised by the reaction format or use of a specific feature the purpose or use of
    • C12Q2537/16—Assays for determining copy number or wherein the copy number is of special importance
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N15/00—Investigating characteristics of particles; Investigating permeability, pore-volume or surface-area of porous materials
    • G01N15/10—Investigating individual particles
    • G01N2015/1006—Investigating individual particles for cytology

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • General Health & Medical Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Dispersion Chemistry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Signal Processing (AREA)
  • Physiology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Computer Vision & Pattern Recognition (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)
EA201891571A 2016-01-06 2017-01-05 Геномное профилирование отдельных циркулирующих опухолевых клеток (ctc) при метастазирующем заболевании для характеризации гетерогенности заболевания EA201891571A1 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662275659P 2016-01-06 2016-01-06
US201662344703P 2016-06-02 2016-06-02
PCT/US2017/012317 WO2017120324A1 (en) 2016-01-06 2017-01-05 Single cell genomic profiling of circulating tumor cells (ctcs) in metastatic disease to characterize disease heterogeneity

Publications (1)

Publication Number Publication Date
EA201891571A1 true EA201891571A1 (ru) 2019-01-31

Family

ID=59273946

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201891571A EA201891571A1 (ru) 2016-01-06 2017-01-05 Геномное профилирование отдельных циркулирующих опухолевых клеток (ctc) при метастазирующем заболевании для характеризации гетерогенности заболевания

Country Status (8)

Country Link
US (2) US20190025312A1 (https=)
EP (1) EP3400311A4 (https=)
JP (3) JP2019502384A (https=)
CN (2) CN115323054A (https=)
AU (2) AU2017205443A1 (https=)
CA (1) CA3010311A1 (https=)
EA (1) EA201891571A1 (https=)
WO (1) WO2017120324A1 (https=)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3045918B1 (en) 2009-10-21 2017-12-06 The Scripps Research Institute Method of using non-rare cells to detect rare cells
EA201691496A1 (ru) 2014-01-27 2016-12-30 Эпик Сайенсиз, Инк. Диагностика биомаркеров рака предстательной железы с помощью циркулирующих опухолевых клеток
EA201691682A1 (ru) 2014-02-21 2017-02-28 Эпик Сайенсиз, Инк. Способы анализирования редких циркулирующих в крови клеток
US11514289B1 (en) 2016-03-09 2022-11-29 Freenome Holdings, Inc. Generating machine learning models using genetic data
US11222194B2 (en) * 2016-12-30 2022-01-11 Ventana Medical Systems, Inc. Automated system and method for creating and executing a scoring guide to assist in the analysis of tissue specimen
EP3431611A1 (en) 2017-07-21 2019-01-23 Menarini Silicon Biosystems S.p.A. Improved method and kit for the generation of dna libraries for massively parallel sequencing
US11348661B2 (en) 2018-05-14 2022-05-31 Tempus Labs, Inc. Predicting total nucleic acid yield and dissection boundaries for histology slides
US10957041B2 (en) 2018-05-14 2021-03-23 Tempus Labs, Inc. Determining biomarkers from histopathology slide images
CN109060989B (zh) * 2018-08-29 2021-07-30 重庆市肿瘤研究所 应用iTRAQ技术研究三阴性乳腺癌外泌体差异表达蛋白的方法
CN109658981B (zh) * 2018-12-10 2022-10-04 海南大学 一种单细胞测序的数据分类方法
EP3991171B1 (en) * 2019-03-26 2025-07-09 Tempus AI, Inc. Determining biomarkers from histopathology slide images
KR102343947B1 (ko) * 2019-09-30 2021-12-27 주식회사 피디젠 환자 정보 분석을 이용한 암 재발 및 전이 모니터링 시스템을 이용한 비즈니스모델
EP3965119A1 (en) * 2020-09-04 2022-03-09 Koninklijke Philips N.V. Methods for estimating heterogeneity of a tumour based on values for two or more genome mutation and/or gene expression related parameter, as well as corresponding devices
CN112164420B (zh) * 2020-09-07 2021-07-20 厦门艾德生物医药科技股份有限公司 一种基因组瘢痕模型的建立方法
WO2022225995A1 (en) * 2021-04-19 2022-10-27 F. Hoffmann-La Roche Ag Methods and systems for gene alteration prediction from pathology slide images
EP4445141A1 (en) * 2021-12-07 2024-10-16 Epic Sciences, Inc. Enhanced characterization of breast cancer
JP2025505920A (ja) * 2021-12-21 2025-03-05 ファウンデーション・メディシン・インコーポレイテッド ゲノムプロファイリングの成功を予測するための方法及びシステム

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2886923T3 (es) * 2005-09-20 2021-12-21 Menarini Silicon Biosystems Spa Métodos y composición para generar sondas de ADN de secuencia única, marcaje de sondas de ADN y el uso de estas sondas
DK2981624T3 (da) 2013-04-05 2020-03-02 Myriad Genetics Inc Fremgangsmåder til vurdering af homolog rekombinationsdeficiens og forudsigelse af respons på cancerbehandling
US20160266127A1 (en) 2013-09-30 2016-09-15 Peter Kuhn Genotypic and Phenotypic Analysis of Circulating Tumor Cells to Monitor Tumor Evolution in Prostate Cancer Patients
CA2937051A1 (en) * 2014-01-17 2015-07-23 Ontario Institute For Cancer Research (Oicr) Biopsy-driven genomic signature for prostate cancer prognosis
WO2015112999A1 (en) * 2014-01-27 2015-07-30 Epic Sciences, Inc. Detection of prostate specific membrane antigen (psma) expression on circulating tumor cells (ctc)
EA201691496A1 (ru) * 2014-01-27 2016-12-30 Эпик Сайенсиз, Инк. Диагностика биомаркеров рака предстательной железы с помощью циркулирующих опухолевых клеток
EP3100052B1 (en) * 2014-01-30 2021-03-10 Epic Sciences, Inc. Circulating tumor cell diagnostics for biomarkers predictive of resistance to androgen receptor (ar) targeted therapies

Also Published As

Publication number Publication date
JP2023116530A (ja) 2023-08-22
JP2019502384A (ja) 2019-01-31
AU2017205443A1 (en) 2018-07-19
CN108884494A (zh) 2018-11-23
AU2023202282A1 (en) 2023-05-11
JP2021118689A (ja) 2021-08-12
EP3400311A4 (en) 2019-07-03
CA3010311A1 (en) 2017-07-13
US20220390451A1 (en) 2022-12-08
WO2017120324A1 (en) 2017-07-13
EP3400311A1 (en) 2018-11-14
CN115323054A (zh) 2022-11-11
US20190025312A1 (en) 2019-01-24

Similar Documents

Publication Publication Date Title
EA201891571A1 (ru) Геномное профилирование отдельных циркулирующих опухолевых клеток (ctc) при метастазирующем заболевании для характеризации гетерогенности заболевания
Esmaeilsabzali et al. Detection and isolation of circulating tumor cells: principles and methods
EA201891085A1 (ru) Получение геномных профилей отдельных клеток для циркулирующих клеток опухолей (ctc) при метастазирующем заболевании для характеризации гетерогенности заболевания
MX390772B (es) Métodos para tratar cáncer y el uso de biomarcadores como predictor de sensibilidad clínica a terapias.
EA201691352A1 (ru) Диагностика рака легкого с помощью циркулирующих опухолевых клеток
EA201691499A1 (ru) Диагностика с помощью циркулирующих опухолевых клеток биомаркеров, позволяющих предсказывать резистентность по отношению к направленным на андрогеновый рецептор (ar) терапиям
MX361058B (es) Método para detectar células tumorales circulantes 5t4-positivas y métodos de diagnóstico de cáncer 5t4-positivo en un sujeto mamífero.
MX360264B (es) Analisis mutacional de adn de plasma para la deteccion de cancer.
RU2013101996A (ru) Диагностика и лечение рака молочной железы
EA201891304A1 (ru) ИНГИБИТОРЫ MAT2A ДЛЯ ЛЕЧЕНИЯ MTAP-null ЗЛОКАЧЕСТВЕННЫХ ОПУХОЛЕЙ
GB2545361A (en) Protein biomarker panels for detecting colorectal cancer and advanced adenoma
NZ629074A (en) Biomarkers for gastric cancer and uses thereof
JP2020522697A5 (https=)
WO2011112903A3 (en) Quantitative rt-pcr detection for genes involved in epithelial mesenchymal transition in peripheral blood of breast cancer patients
BR112016013976A2 (pt) método para determinar se um indivíduo é afetado por um câncer, método para discriminar entre câncer colorretal e pancreático dentre indivíduos que resultam ser positivos para o método, método para determinar o estágio de um câncer colorretal em um indivíduo afetado e uso de um kit de rt-pcr quantitativo para performar o método
GB2480980A (en) Methods for predicting cancer response to EGFR inhibitors
MX2021003214A (es) Metodos terapeuticos y de diagnostico para el cancer de vejiga.
ATE545867T1 (de) I-plastin-testverfahren zur in-vitro-diagnose von kolorektalkarzinom
GB2523211A (en) MCT protein inhibitor-related prognostic and therapeutic methods
PH12018501813A1 (en) Early detection of hepatocellular carcinoma
EA201890816A1 (ru) Вариант 7as андрогенового рецептора как биомаркер для выбора лечения пациентов с метастатическим раком простаты, резистентным к кастрации (mcrpc)
EA201690995A1 (ru) Способы обнаружения и количественного анализа циркулирующих эндотелиальных клеток
LI et al. Correlation between expression of C-met and epidermal growth factor receptor-tyrosine kinase inhibitor resistance in lung adenocarcinoma
Stone You’ve got a friend online
MENG et al. Expression of lncRNA BC200 in non-small cell lung cancer and its significance